Structure Therapeutics (NASDAQ:GPCR - Get Free Report) is expected to be announcing its earnings results before the market opens on Friday, March 14th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. On average, analysts expect Structure Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Structure Therapeutics Stock Down 10.9 %
Structure Therapeutics stock traded down $2.46 during mid-day trading on Monday, reaching $20.16. 859,499 shares of the company's stock were exchanged, compared to its average volume of 823,021. The company has a market cap of $1.15 billion, a P/E ratio of -27.24 and a beta of -2.37. Structure Therapeutics has a twelve month low of $19.61 and a twelve month high of $62.74. The company has a fifty day moving average of $25.98 and a 200-day moving average of $33.01.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on GPCR. William Blair initiated coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating on the stock. JMP Securities reissued a "market outperform" rating and set a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $81.29.
View Our Latest Analysis on Structure Therapeutics
About Structure Therapeutics
(
Get Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Articles
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
